SCHEMBL22234652

SCHEMBL22234652

O=C(Cl)c1cccc(C(F)CF)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGK1 P00558 2/20 0.40
PGK2 P07205 2/20 0.40
TDP1 Q9NUW8 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
ACMSD Q8TDX5 1/20 0.34
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
P2RX7 Q99572 2/20 0.31
GRM4 Q14833 1/20 0.31
CNR2 P34972 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30
RECQL P46063 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22235148 0.85 KDM4E (0.53) PGK1PGK2TDP1KDM4EALOX15
SCHEMBL22235092 0.83 PIM1 (0.39) PGK1PGK2TDP1KDM4EALOX15
SCHEMBL18839188 0.82 PGK1 (0.44) PGK1PGK2TDP1KDM4EALOX15
SCHEMBL22234628 0.80 MAPT (0.46) KDM4ETSHRCYP1A2NPC1ALDH1A1
SCHEMBL321127 0.73 KDM4E (0.59) TDP1KDM4EALOX15TSHRACMSD
SCHEMBL22834638 0.71 SMN1; SMN2 (0.41) KDM4ENPC1LMNARAB9ASMN1; SMN2
SCHEMBL28715318 0.70 MEN1 (0.36) PGK1PGK2
SCHEMBL22834473 0.69 NOS3 (0.39) PGK1PGK2GRM4
SCHEMBL22834772 0.69 S1PR2 (0.35) PGK1PGK2IRAK4
SCHEMBL29651899 0.69 NOS3 (0.39) PGK1PGK2GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. 2022-03-24 US disclosed
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. 2022-03-24 US disclosed
EP-3911652-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS Biogen MA Inc. (US) 2021-11-24 EP disclosed
WO-2020150626-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. (US) 2020-07-23 WO disclosed
WO-2020150626-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. (US) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS IRAK4, IRAK2, IRAK1 PGK1 2881/4885PGK2 3045/4885TDP1 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.